Trend Aggregation Conservative ETF TACE
25.59 USD 0.00 (+0.00%)
Sep 22, 2021, 3:59 PM EDT
25.55 Day range 25.60
23.82 52-week range 25.83
News
gurufocus.com IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
gurufocus.com Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
defenseworld.net Trend Aggregation Conservative ETF (NYSEARCA:TACE) Stock Price Down 0.2% – Time to Sell? Trend Aggregation Conservative ETF (NYSEARCA:TACE - Get Free Report)'s share price fell 0.2% during mid-day trading on Friday. The company traded as low as $25.55 and last traded at $25.59.…
businesswire.com IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and…
gurufocus.com Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types PR Newswi
gurufocus.com IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
defenseworld.net Trend Aggregation Conservative ETF (NYSEARCA:TACE) Shares Down 0.2% – Should You Sell? Shares of Trend Aggregation Conservative ETF (NYSEARCA:TACE - Get Free Report) dropped 0.2% on Tuesday. The stock traded as low as $25.55 and last traded at $25.59. Approximately 5,700 shares were…
businesswire.com KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable,…
etf.com ETF Odds & Ends: 2 Closures Announced Plus, a number of fund names have changed.
etf.com ETF Odds & Ends: Veterans Fund Closes Plus, Direxion launches a leveraged clean energy ETF.